Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aytu BioPharma Q1 Adj. EPS $(0.08) Beats $(0.23) Estimate, Sales $13.900M Beat $12.397M Estimate

Author: Benzinga Newsdesk | November 13, 2025 04:09pm
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.23) by 65.22 percent. This is a 60 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $13.900 million which beat the analyst consensus estimate of $12.397 million by 12.12 percent. This is a 16.13 percent decrease over sales of $16.574 million the same period last year.

Posted In: AYTU


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist